UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15 (d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported) April
25, 2005
ADVENTRX
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
(State or
other jurisdiction of incorporation)
|
001-32157
(Commission
File Number) |
|
84-1318182
(IRS
Employer Identification No.) |
6725
Mesa Ridge Road, Suite 100
San
Diego, California 92121
(Address
of principal executive offices) (Zip Code)
(858)
552-0866
(Company’s
telephone number, including area code)
Item
8.01. Other Events.
On April
25, 2005, the Company announced that it received FDA clearance for its CoFactor
Phase III pivotal trial in metastatic colorectal cancer.
The press
release issued by the Company on April 25, 2005 with respect to this matter is
included with this report as anexhibit.
Item
9.01. Financial Statements and Exhibits.
| (99) |
©The
exhibit list required by this item is incorporated by reference to the
Exhibit Index filed as part of this report. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
|
|
| |
ADVENTRX
Pharmaceuticals, Inc. |
|
|
|
|
By: |
/s/ Carrie E.
Carlander |
| |
Name:
Carrie E. Carlander |
| |
Title:
Chief Financial Officer, Vice President, Finance, and
Treasurer |
| |
|
| |
April
25, 2005 |
EXHIBIT
INDEX
|
Exhibit
|
Description
|
|
99.1
|
Press
Release of the Company dated April 25, 2005.
|